Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2012-10-02
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-10-22 (study day 21.0); relationship: PROBABLE
mild
assessed
Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-02 (study day 62.0); relationship: PROBABLE
mild
assessed
Mild APPLICATION SITE VESICLES — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-25 (study day 85.0); relationship: PROBABLE
mild
assessed
Mild APPLICATION SITE VESICLES — outcome: RECOVERED/RESOLVED; onset 2012-12-25 (study day 85.0); relationship: PROBABLE
Data queries
No data queries.